ClinicalTrials.gg
CompletedNCT02833350Updated Jun 12, 2020Results posted

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

A Phase 2 interventional study of GDC-0853 and Adalimumab in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Completed at 150 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-12.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
578
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Hoffmann-La Roche.

Enrollment
19th of 141
578 · median 132
Started
2016
with 7 others
Phase 2
20 of 219
2 open now
Registered
212th of 219
by date

Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 19th largest by enrollment of the 141 interventional ones that give a count, is one of 8 that started in 2016, is one of 20 in phase 2, and was the 212th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, active comparator (Cohort 1 only), parallel-group, dose-ranging study to evaluate the efficacy and safety of GDC-0853 in participants with moderate to severe active RA and an inadequate response to previous methotrexate (MTX) therapy (Cohort 1) or MTX and tumor necrosis factor (TNF) therapy who may have also had exposure to no more than one non-TNF inhibitor biologic (Cohort 2).

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of adult-onset RA as defined by the 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria for RA
  • RA disease activity by joint counts and laboratory markers of inflammation: greater than or equal to (>=) 6 tender/painful joints on motion (68 joint count) and >= 6 swollen joints (66 joint count) at both screening and Day 1 (randomization)
  • For MTX-inadequate response (IR) participants: must have had an inadequate response to MTX
  • For TNF-IR participants: must have had an inadequate response or intolerance to previous treatment with at least 1 and no more than 2 biologic TNF-alpha inhibitors and may have also been exposed to no more than one biologic non-TNF-alpha inhibitor
  • High sensitivity C-reactive protein of >= 0.400 milligrams per deciliter (mg/dL) for Cohort 1 and >= 0.650 mg/dL for Cohort 2 at screening

Exclusion criteria

Exclusion Criteria:

  • History of or current inflammatory joint disease other than RA or other systemic disorder
  • For MTX-IR participants: History of treatment with any TNF inhibitor, including biosimilar equivalents and history of treatment with biologic non-TNF-alpha inhibitor for RA
  • For all participants: Previous treatment with cell-depleting therapy including B cell-depleting therapy (e.g., anti-cluster of differentiation 20-directed therapy such as rituximab), tofacitinib, or other Janus kinase inhibitor(s), or alkylating agents
  • Current treatment with medications that are well known to prolong the at doses that have a effect on QT
  • History of non-gallstone-related pancreatitis or chronic pancreatitis
  • Evidence of serious uncontrolled concomitant cardiac, neurologic, pulmonary, renal, hepatic, endocrine, metabolic, or gastrointestinal disease
  • Evidence of chronic and/or active or C
  • Women who are pregnant, nursing (breast feeding), or intending to become pregnant during the study or within 60 days after completion of the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
578 participants (actual)

Study arms

  • Experimental
    Cohort 1: GDC-0853 High Dose + Adalimumab Placebo

    Participants of Cohort 1 will receive GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.

    Drug: GDC-0853 · Drug: Folic Acid · Drug: MTX · Drug: Placebo

  • Experimental
    Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo

    Participants of Cohort 1 will receive GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.

    Drug: GDC-0853 · Drug: Folic Acid · Drug: MTX · Drug: Placebo

  • Experimental
    Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo

    Participants of Cohort 1 will receive GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.

    Drug: GDC-0853 · Drug: Folic Acid · Drug: MTX · Drug: Placebo

  • Active comparator
    Cohort 1: GDC-0853 Placebo + Adalimumab

    Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.

    Drug: Adalimumab · Drug: Folic Acid · Drug: MTX · Drug: Placebo

  • Placebo comparator
    Cohort 1: GDC-0853 Placebo + Adalimumab Placebo

    Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.

    Drug: Folic Acid · Drug: MTX · Drug: Placebo

  • Experimental
    Cohort 2: GDC-0853 High Dose

    Participants of Cohort 2 will receive GDC-0853 high dose, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.

    Drug: GDC-0853 · Drug: Folic Acid · Drug: MTX

  • Placebo comparator
    Cohort 2: GDC-0853 Placebo

    Participants of Cohort 2 will receive placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.

    Drug: Folic Acid · Drug: MTX · Drug: Placebo

Interventions

  • Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.

    Also known as: RO7010939

  • Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.

  • Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.

  • DrugMTX

    Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).

  • DrugPlacebo

    Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 1)

    ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

    Time frame: Day 84

  2. Percentage of Participants With Adverse Events

    An Adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE was any experience that suggested a significant hazard, contraindication, side effect or precaution that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant.

    Time frame: Day 1 up to 8 weeks after last dose (up to Week 20)

Secondary outcomes

  1. Percentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Adalimumab (Cohort 1)

    ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

    Time frame: Day 84

  2. Percentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 2)

    ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

    Time frame: Day 84

  3. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response

    ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\]

    Time frame: Days 7, 14, 28, 56, and 84

  4. Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response

    ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

    Time frame: Days 7, 14, 28, 56, and 84

  5. Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response

    ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

    Time frame: Days 7, 14, 28, 56, and 84

  6. Change in Disease Activity Score From Baseline Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

    Time frame: Days 7, 14, 28, 56, and 84

  7. Change in Disease Activity Score From Baseline Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

    Time frame: Days 7, 14, 28, 56, and 84

  8. Change in Disease Activity Score From Baseline Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR])

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

    Time frame: Days 7, 14, 28, 56, and 84

  9. Change in Disease Activity Score From Baseline Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

    Time frame: Days 7, 14, 28, 56, and 84

  10. Percentage of Participants With DAS Low Disease Activity

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. LDAS is defined as DAS28 ≤ 3.2

    Time frame: Days 7, 14, 28, 56, and 84

  11. Percentage of Participants With DAS Remission

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6

    Time frame: Days 7, 14, 28, 56, and 84

  12. Percentage of Participants Meeting the Boolean-based Remission Criteria

    Boolean Remission is defined as Tender joint count less than 1, Swollen joint count less than 1, CRP less than 1 mg/dL, patient global assessment less than 1 (on 0 to 10 VAS scale).

    Time frame: Days 7, 14, 28, 56, and 84

  13. Change From Baseline in Clinical Disease Activity Index (CDAI)

    CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest. Negative values indicate improvement/reduction in RA disease activity.

    Time frame: Baseline, Days 7, 14, 28, 56 and 84

  14. Percentage of Participants Meeting the CDAI-based Remission Criteria

    Clinical Disease Activity Index is defined as CDAI= : SJC(28) + TJC(28) + PGA + MDG where TJC and SJC are the tender and swollen joint counts from 28 joints, PGA is the patient's global assessment of disease activity (on a 0-10 scale) and MDG is physician global assessment of disease activity (on a 0-10 scale). The cutoff value for CDAI remission is \<=2.8.

    Time frame: Days 7, 14, 28, 56, and 84

  15. Change From Baseline in Simplified Disease Activity Index (SDAI)

    Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity

    Time frame: Baseline, Days 7, 14, 28, 56 and 84

  16. Percentage of Participants Meeting the SDAI-based Remission Criteria

    The SDAI was the numerical sum of five outcome parameter: SJC and TJC (based on a 28-joint assessment), PGA and MDG (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. The SDAI =\< 3.3 indicates disease remission

    Time frame: Days 7, 14, 28, 56, and 84

  17. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Version 2.0 (V2) Scores for Physical and Mental Components

    The 36-Item Short Form Health Survey (SF-36v2) is a questionnaire used to assess functional health and well-being and consists of eight domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. The SF-36v2 is summarized into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. The PCS and MCS scores range from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.

    Time frame: Day 84

  18. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score

    The FACIT-Fatigue Scale consists of 13 items designed to measure the degree of fatigue experienced by the patient in the previous 7 days. For each question, there are five possible responses: 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much). A total fatigue score is calculated by summing all items, and possible total scores range from 0 (maximum fatigue) to 52 (no fatigue). A positive change from baseline indicates an improvement in the patient's fatigue (less fatigue).

    Time frame: Day 84

  19. Change From Baseline in Tender/Painful Joint Count (68 Joint Count)

    Tender Joint Count: a total of 68 joints will be assessed for tenderness. Each joint is assessed for the presence/absence of tenderness. 68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.

    Time frame: Days 7, 14, 28, 56, and 84

  20. Change From Baseline in Swollen Joint Count (66 Joint Count)

    Swollen Joint Count: a total of 66 joints will be assessed for swelling. Each joint is assessed for the presence/absence of swelling. 66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.

    Time frame: Days 7, 14, 28, 56, and 84

  21. Change From Baseline in Patient Assessment Score of Arthritis Pain

    Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain

    Time frame: Days 7, 14, 28, 56, and 84

  22. Change From Baseline in Patient Global Assessment Score of Arthritis Pain

    Participant-assessed arthritis pain was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of arthritis pain (0 mm=none; 100 mm=very severe). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change indicated a decrease in participant-assessed arthritis pain.

    Time frame: Days 7, 14, 28, 56, and 84

  23. Change From Baseline in Physician's Global Assessment Score of Arthritis

    Physician's assessment of participant's disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the physician's assessment of the participant's disease activity (0 mm=very good; 100 mm=very poor). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change from baseline indicated an improvement in physician-assessed disease activity.

    Time frame: Days 7, 14, 28, 56, and 84

  24. Change From Baseline in C-Reactive Protein (CRP) Levels

    C-reactive protein is a biological marker of inflammation and is measured in nanograms per milliliter (ng/mL)

    Time frame: Days 7, 14, 28, 56, and 84

  25. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

    The Stanford Health Assessment Questionnaire disability index is a patient-reported outcome used to assess difficulty in performing activities of daily living. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. To respond to each question, a four-level response with higher scores showing larger functional limitations, was chosen. Scoring is as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. The composite HAQ-DI score is the mean of the eight domain scores and the score ranges from 0 (no functional impairment) to 3 (maximum functional impairment). A negative change from baseline indicates improvement.

    Time frame: Days 7, 14, 28, 56, and 84

  26. Area Under the Concentration Time Curve From Time 0 to Time 24 of GDC-0853 at Steady State (AUC0-24,ss)

    The Pharmacokinetics (PK) evaluation may include, but will not be limited to, plasma GDC-0853 concentrations and population PK model estimated PK exposures (area under the plasma concentration-time curve \[AUC\]. AUC was measured in Nanograms(ng) per millilitre(mL)\*hour (hr)

    Time frame: Pre-dose (0 hours) up to 10 hours post-dose on Day 28

  27. Maximum Observed Plasma Concentration of GDC-0853 at Steady State (Cmax,ss)

    Cmax is the maximum (peak) plasma concentration over the dosing interval at steady state (ss)

    Time frame: Pre-dose (0 hours) up to 10 hours post-dose on Day 28

  28. Minimum Observed Plasma Concentration of GDC-0853 at Steady State (Cmin,ss)

    Cmin is the minimum concentration over the dosing interval at steady state (ss)

    Time frame: Pre-dose (0 hours) up to 10 hours post-dose on Day 28

07

Results

Posted Sep 10, 2019

Participant flow

578 participants were enrolled in the study and 578 were dosed. One (1) subject in Cohort 2 in the Placebo arm was incorrectly dosed with the High Dose. The ITT data set included participants according to their randomization while SAF data set included participants according to the treatment administered.

Participant flow — Overall Study
MilestoneCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Started401091101101114949
Randomized401091101101114850
Completed371001021021084844
Not completed3988315
Withdrew: Adverse event0344101
Withdrew: Death0010000
Withdrew: Lack of efficacy0214011
Withdrew: Lost to follow-up0100001
Withdrew: Withdrawal by subject3320202

Outcome measures

PrimaryPercentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 1)

ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

Time frame:
Day 84
Reported as:
Number · Percentage
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 1)
PercentageCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 1)17.5 (5.72 to 29.28)27.5 (19.14 to 35.91)34.5 (25.66 to 43.43)14.5 (7.96 to 21.13)36.0 (27.10 to 44.97)
Statistical analysis
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.2503 · Weighted difference: 8.00 · 95% CI -5.64 to 21.64
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0164 · Weighted difference: 12.93 · 95% CI 2.37 to 23.48
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0003 · Weighted difference: 20.00 · 95% CI 9.21 to 30.79
PrimaryPercentage of Participants With Adverse Events

An Adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events. A SAE was any experience that suggested a significant hazard, contraindication, side effect or precaution that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant.

Time frame:
Day 1 up to 8 weeks after last dose (up to Week 20)
Reported as:
Number · Percentage
Percentage of Participants With Adverse Events
PercentageCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Percentage of Participants With Adverse Events37.542.250.945.545.022.444.9
SecondaryPercentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Adalimumab (Cohort 1)

ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

Time frame:
Day 84
Reported as:
Number · Percentage
Percentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Adalimumab (Cohort 1)
PercentageCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab
Percentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Adalimumab (Cohort 1)17.5 (5.72 to 29.28)27.5 (19.14 to 35.91)34.5 (25.66 to 43.43)14.5 (7.96 to 21.13)36.0 (27.10 to 44.97)
Statistical analysis
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.1694 · Weighted difference: -8.58 · 95% CI -20.82 to 3.66
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.8132 · Weighted difference: -1.50 · 95% CI -13.96 to 10.95
SecondaryPercentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 2)

ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

Time frame:
Day 84
Reported as:
Number · Percentage
Percentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 2)
PercentageCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Percentage of Participants Achieving ACR50 Response at Day 84, Comparison Between GDC-0853 and Placebo (Cohort 2)25.0 (12.75 to 37.25)12.0 (2.99 to 21.01)
Statistical analysis
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.0717 · Weighted difference: 13.7 · 95% CI -1.21 to 28.61
SecondaryPercentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response

ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\]

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Number · Percentage
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response
PercentageCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 710.0 (.70 to 19.3)14.7 (8.04 to 21.32)13.6 (7.22 to 20.05)10.0 (4.39 to 15.61)25.2 (17.15 to 33.30)22.9 (11.03 to 34.81)2.0 (0.00 to 5.88)
Week 2 Day 1412.5 (2.25 to 22.75)19.3 (11.86 to 26.67)27.3 (18.95 to 35.60)16.4 (9.45 to 23.28)48.6 (39.35 to 57.95)25.0 (12.75 to 37.25)10.0 (1.68 to 18.32)
Week 4 Day 2830.0 (15.80 to 44.20)34.9 (25.92 to 43.81)41.8 (32.60 to 51.04)25.5 (17.31 to 33.59)59.5 (50.33 to 68.59)35.4 (21.89 to 48.95)24.0 (12.16 to 35.84)
Week 8 Day 5650.0 (34.51 to 65.49)52.3 (42.92 to 61.67)58.2 (48.96 to 67.40)37.3 (28.24 to 46.31)71.2 (62.74 to 79.60)47.9 (33.78 to 62.05)18.0 (7.35 to 28.65)
Week 12 Day 8460.0 (44.82 to 75.18)56.0 (46.64 to 65.28)59.1 (49.90 to 68.28)36.4 (27.37 to 45.35)72.1 (63.73 to 80.42)58.3 (44.39 to 72.28)24.0 (12.16 to 35.84)
SecondaryPercentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response

ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Number · Percentage
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response
PercentageCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 72.5 (0.00 to 7.34)2.8 (0.00 to 5.82)3.6 (0.14 to 7.13)2.7 (0.00 to 5.77)4.5 (0.65 to 8.36)6.3 (0.00 to 13.10)2.0 (0.00 to 5.88)
Week 2 Day 140.0 (0.00 to 0.00)1.8 (0.00 to 4.35)7.3 (2.42 to 12.13)2.7 (0.00 to 5.77)9.0 (3.68 to 14.34)10.4 (1.77 to 19.06)0.00 (0.00 to 0.00)
Week 4 day 285.0 (0.00 to 11.75)9.2 (3.76 to 14.59)10.0 (4.39 to 15.61)6.4 (1.80 to 10.93)25.2 (17.15 to 33.30)10.4 (1.77 to 19.06)6.0 (0.00 to 12.58)
Week 8 Day 5615.0 (3.93 to 26.07)18.3 (11.08 to 25.62)22.7 (14.9 to 30.56)17.3 (10.21 to 24.34)32.4 (23.72 to 41.14)22.9 (11.03 to 34.81)10.0 (1.68 to 18.32)
Week 12 Day 8417.5 (5.72 to 29.28)27.5 (19.14 to 35.91)34.5 (25.66 to 43.43)14.5 (7.96 to 21.13)36.0 (27.10 to 44.97)25.0 (12.75 to 37.25)12.0 (2.99 to 21.01)
SecondaryPercentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response

ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Number · Percentage
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
PercentageCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 70.0 (0.00 to 0.00)0.9 (0.00 to 2.71)0.9 (0.00 to 2.68)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)
Week 2 Day 140.0 (0.00 to 0.00)0.9 (0.00 to 2.71)0.0 (0.00 to 0.00)0.00 (0.00 to 0.00)3.6 (0.14 to 7.07)4.2 (0.00 to 9.82)0.0 (0.00 to 0.00)
Week 4 Day 280 (0.00 to 0.00)2.8 (0.00 to 5.82)4.5 (0.65 to 8.44)0.9 (0.00 to 2.68)6.3 (1.78 to 10.83)2.1 (0.00 to 6.12)2.0 (0.00 to 5.88)
Week 8 Day 560.0 (0.00 to 0.00)7.3 (2.44 to 12.24)9.1 (3.72 to 14.46)3.6 (0.14 to 7.13)14.4 (7.88 to 20.95)6.3 (0.00 to 13.10)4.0 (0.00 to 9.43)
Week 12 Day 845.0 (0.00 to 11.75)9.2 (3.76 to 14.59)12.7 (6.50 to 18.96)7.3 (2.42 to 12.13)18.0 (10.87 to 25.17)14.6 (4.60 to 24.57)4.0 (0.00 to 9.43)
SecondaryChange in Disease Activity Score From Baseline Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Mean · Score on a scale
Change in Disease Activity Score From Baseline Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])
Score on a scaleCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 7-0.34 ± 0.60-0.35 ± 0.66-0.37 ± 0.80-0.33 ± 0.84-0.92 ± 0.71-0.49 ± 0.84-0.36 ± 0.63
Week 2 Day 14-0.47 ± 0.72-0.63 ± 0.84-0.70 ± 0.80-.54 ± 0.90-1.09 ± 0.81-0.65 ± 0.87-0.45 ± 0.69
Week 4 Day 28-0.75 ± 0.86-0.90 ± 0.96-0.91 ± 0.97-0.62 ± 1.04-1.45 ± 0.87-0.77 ± 0.90-0.44 ± 0.84
Week 8 Day 56-1.14 ± 0.90-1.35 ± 1.12-1.37 ± 1.11-1.08 ± 1.19-1.75 ± 0.98-1.33 ± 0.98-0.56 ± 0.87
Week 12 Day 84-1.30 ± 0.95-1.72 ± 1.11-1.70 ± 1.02-1.17 ± 1.24-1.87 ± 1.02-1.62 ± 1.15-0.86 ± 1.03
Statistical analysis
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.8504 · Adjusted difference: -0.11 · 95% CI -0.45 to 0.23
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.9884 · Adjusted difference: -0.04 · 95% CI -0.28 to 0.21
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.9230 · Adjusted difference: -0.06 · 95% CI -0.31 to 0.18
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.9853 · Adjusted difference: -0.06 · 95% CI -0.43 to 0.31
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.6826 · Adjusted difference: -0.12 · 95% CI -0.38 to 0.15
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.2634 · Adjusted difference: -0.18 · 95% CI -0.45 to 0.08
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.2885 · Adjusted difference: -0.29 · 95% CI -0.72 to 0.14
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0598 · Adjusted difference: -0.30 · 95% CI -0.61 to 0.01
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0440 · Adjusted difference: -0.31 · 95% CI -0.62 to -0.01
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.4271 · Adjusted difference: -0.28 · 95% CI -0.76 to 0.20
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0969 · Adjusted difference: -0.31 · 95% CI -0.66 to 0.04
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0612 · Adjusted difference: -0.33 · 95% CI -0.68 to 0.01
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.2079 · Adjusted difference: -0.36 · 95% CI -0.84 to 0.12
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0003 · Adjusted difference: -0.57 · 95% CI -0.92 to -0.22
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0003 · Adjusted difference: -0.57 · 95% CI -0.92 to -0.22
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = <.0001 · Adjusted difference: 0.58 · 95% CI 0.34 to 0.82
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = <0.0001 · Mean difference (net): 0.55 · 95% CI 0.31 to 0.80
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = <.0001 · Adjusted difference: 0.47 · 95% CI 0.20 to 0.74
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0009 · Adjusted difference: 0.40 · 95% CI 0.13 to 0.66
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = <.0001 · Adjusted difference: 0.56 · 95% CI 0.25 to 0.87
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = <.0001 · Adjusted difference: 0.55 · 95% CI 0.24 to 0.85
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0095 · Adjusted difference: 0.42 · 95% CI 0.08 to 0.76
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0153 · Adjusted difference: 0.40 · 95% CI 0.06 to 0.74
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.4839 · Adjusted difference: 0.19 · 95% CI -0.16 to 0.54
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.5035 · Adjusted difference: 0.19 · 95% CI -0.16 to 0.53
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.4286 · Adjusted difference: -0.11 · 95% CI -0.38 to 0.16
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.1831 · Adjusted difference: -0.20 · 95% CI -0.50 to 0.10
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.0667 · Adjusted difference: -0.31 · 95% CI -0.65 to 0.02
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = <0.0001 · Adjusted difference: -0.77 · 95% CI -1.11 to -0.42
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.0002 · Adjusted difference: -0.76 · 95% CI -1.15 to -0.38
SecondaryChange in Disease Activity Score From Baseline Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Mean · Score on a scale
Change in Disease Activity Score From Baseline Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])
Score on a scaleCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 7-0.43 ± 0.67-0.48 ± 0.73-0.49 ± 0.86-0.37 ± 0.91-1.10 ± 0.75-0.63 ± 0.91-.40 ± 0.69
Week 2 Day 14-0.51 ± 0.85-0.77 ± 0.86-0.84 ± 0.86-0.57 ± 1.00-1.26 ± 0.89-0.81 ± 0.98-0.54 ± 0.80
Week 4 Day 28-0.88 ± 0.90-1.06 ± 1.02-1.08 ± 1.03-0.65 ± 1.16-1.61 ± 0.94-0.95 ± 1.04-0.55 ± 0.94
Week 8 Day 56-1.31 ± 0.91-1.56 ± 1.21-1.57 ± 1.161.20 ± 1.30-1.97 ± 1.03-1.51 ± 1.05-0.67 ± 1.01
Week 12 Day 84-1.53 ± 0.95-1.97 ± 1.20-1.93 ± 1.11-1.33 ± 1.33-2.06 ± 1.08-1.83 ± 1.22-1.00 ± 1.11
Statistical analysis
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.5807 · Adjusted difference: -0.18 · 95% CI -0.55 to 0.19
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.6270 · Adjusted difference: -0.12 · 95% CI -0.39 to 0.14
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.4475 · Adjusted difference: -0.15 · 95% CI -0.42 to 0.12
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.9891 · Adjusted difference: -0.06 · 95% CI -0.47 to 0.35
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.2244 · Adjusted difference: -0.21 · 95% CI -0.51 to 0.08
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0586 · Adjusted difference: -0.28 · 95% CI -0.58 to 0.01
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.1338 · Adjusted difference: -0.39 · 95% CI -0.85 to 0.08
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0119 · Adjusted difference: -0.40 · 95% CI -0.74 to -0.07
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0046 · Adjusted difference: -0.44 · 95% CI -0.77 to -0.11
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.3943 · Adjusted difference: -0.31 · 95% CI -0.82 to 0.20
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0526 · Adjusted difference: -0.37 · 95% CI -0.74 to 0.00
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0365 · Adjusted difference: -0.39 · 95% CI -0.76 to -0.02
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.1696 · Adjusted difference: -0.41 · 95% CI -0.93 to 0.11
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0002 · Adjusted difference: -0.63 · 95% CI -1.01 to -0.25
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0003 · Adjusted difference: -0.62 · 95% CI -1.00 to -0.24
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = <0.0001 · Adjusted difference: 0.64 · 95% CI 0.37 to 0.90
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = <0.0001 · Adjusted difference: 0.61 · 95% CI 0.34 to 0.88
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0001 · Adjusted difference: 0.50 · 95% CI 0.21 to 0.79
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0012 · Adjusted difference: 0.43 · 95% CI 0.14 to 0.72
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = <0.0001 · Adjusted difference: 0.58 · 95% CI 0.25 to 0.91
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0002 · Adjusted difference: 0.54 · 95% CI 0.21 to 0.87
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0084 · Adjusted difference: 0.46 · 95% CI 0.09 to 0.82
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0124 · Adjusted difference: 0.44 · 95% CI 0.07 to 0.80
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.7565 · Adjusted difference: 0.15 · 95% CI -0.23 to 0.52
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.7158 · Adjusted difference: 0.16 · 95% CI -0.22 to 0.53
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.1368 · Adjusted difference: -0.22 · 95% CI -0.52 to 0.07
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.0974 · Adjusted difference: -0.28 · 95% CI -0.62 to 0.05
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.0479 · Adjusted difference: -0.38 · 95% CI -0.76 to -0.00
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = <0.0001 · Adjusted difference: -0.84 · 95% CI -1.22 to -0.46
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.0001 · Adjusted difference: -0.83 · 95% CI -1.24 to -0.42
SecondaryChange in Disease Activity Score From Baseline Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR])

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Mean · Score on a scale
Change in Disease Activity Score From Baseline Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR])
Score on a scaleCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 7-0.35 ± 0.57-0.42 ± 0.65-0.39 ± 0.68-0.34 ± 0.86-0.72 ± 0.72-0.50 ± 0.73-0.31 ± 0.60
Week 2 Day 14-0.60 ± 0.89-0.69 ± 0.84-0.68 ± 0.74-0.55 ± 0.92-1.02 ± 0.84-0.64 ± 0.81-0.51 ± 0.73
Week 4 Day 28-0.88 ± 0.89-0.99 ± 0.98-0.97 ± 0.90-0.75 ± 1.02-1.47 ± 1.02-0.85 ± 0.81-0.50 ± 0.83
Week 8 Day 56-1.25 ± 0.85-1.44 ± 1.14-1.40 ± 1.06-1.15 ± 1.19-1.74 ± 0.98-1.35 ± 0.96-0.70 ± 0.98
Week 12 Day 84-1.51 ± 1.01-1.80 ± 1.25-1.80 ± 0.99-1.30 ± 1.22-1.85 ± 1.06-1.65 ± 1.06-0.94 ± 10.6
Statistical analysis
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.9193 · Adjusted difference: -0.09 · 95% CI -0.41 to 0.24
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.7062 · Adjusted difference: -0.10 · 95% CI -0.33 to 0.14
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.8542 · Adjusted difference: -0.08 · 95% CI -0.31 to 0.16
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.8095 · Adjusted difference: -0.13 · 95% CI -0.51 to 0.24
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.3862 · Adjusted difference: -0.17 · 95% CI -0.44 to 0.11
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.4328 · Adjusted difference: -0.16 · 95% CI -0.43 to 0.12
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.4915 · Adjusted difference: -0.24 · 95% CI -0.68 to 0.20
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.1441 · Adjusted difference: -0.26 · 95% CI -0.58 to 0.06
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.1890 · Adjusted difference: -0.24 · 95% CI -0.56 to 0.07
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.5566 · Adjusted difference: -0.25 · 95% CI -0.74 to -0.24
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0920 · Adjusted difference: -0.32 · 95% CI -0.68 to 0.04
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.1391 · Adjusted difference: -0.29 · 95% CI -0.65 to 0.06
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.2873 · Adjusted difference: -0.35 · 95% CI -0.86 to 0.17
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0020 · Adjusted difference: -0.54 · 95% CI -0.91 to -0.16
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0016 · Adjusted difference: -0.54 · 95% CI -0.92 to -0.17
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0050 · Adjusted difference: 0.31 · 95% CI 0.07 to 0.55
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0020 · Adjusted difference: 0.33 · 95% CI 0.10 to 0.57
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0082 · Adjusted difference: 0.35 · 95% CI 0.07 to 0.62
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0056 · Adjusted difference: 0.35 · 95% CI 0.08 to 0.63
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0004 · Adjusted difference: 0.50 · 95% CI 0.19 to 0.82
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0002 · Adjusted difference: 0.52 · 95% CI 0.21 to 0.84
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0650 · Adjusted difference: 0.34 · 95% CI -0.01 to 0.69
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0365 · Adjusted difference: 0.37 · 95% CI 0.02 to 0.72
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.9338 · Adjusted difference: 0.09 · 95% CI -0.28 to 0.47
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.9520 · Adjusted difference: 0.09 · 95% CI -0.29 to 0.46
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.1496 · Adjusted difference: -0.19 · 95% CI -0.45 to 0.07
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.3936 · Adjusted difference: -0.13 · 95% CI -0.43 to 0.17
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.0346 · Adjusted difference: -0.35 · 95% CI -0.68 to -0.03
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.0004 · Adjusted difference: -0.68 · 95% CI -1.04 to -0.31
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.0003 · Adjusted difference: -0.73 · 95% CI -1.11 to -0.34
SecondaryChange in Disease Activity Score From Baseline Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Mean · Score on a scale
Change in Disease Activity Score From Baseline Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])
Score on a scaleCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 7-0.45 ± 0.63-0.54 ± 0.72-0.52 ± 0.77-0.37 ± 0.95-0.93 ± 0.76-0.65 ± 0.80-0.36 ± 0.66
Week 2 Day 14-0.63 ± 0.98-0.85 ± 0.85-0.84 ± 0.82-0.58 ± 1.03-1.22 ± 0.94-0.81 ± 0.92-0.60 ± 0.84
Week 4 Day 28-1.00 ± 0.95-1.16 ± 1.06-1.15 ± 0.98-0.79 ± 1.16-1.65 ± 1.11-1.04 ± 0.95-0.61 ± 0.96
Week 8 Day 56-1.43 ± 0.88-1.67 ± 1.25-1.63 ± 1.14-1.29 ± 1.31-2.00 ± 1.06-1.54 ± 1.04-0.81 ± 1.12
Week 12 Day 84-1.76 ± 1.04-2.06 ± 1.36-2.05 ± 1.08-1.46 ± 1.32-2.08 ± 1.14-1.89 ± 1.15-1.08 ± 1.17
Statistical analysis
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.6083 · Adjusted difference: -0.17 · 95% CI -0.53 to 0.19
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.2672 · Adjusted difference: -0.18 · 95% CI -0.44 to 0.08
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.3158 · Adjusted difference: -0.17 · 95% CI -0.43 to 0.09
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.8495 · Adjusted difference: -0.14 · 95% CI -0.55 to 0.28
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0856 · Adjusted difference: -0.28 · 95% CI -0.58 to 0.03
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.1021 · Adjusted difference: -0.27 · 95% CI -0.57 to 0.04
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.2762 · Adjusted difference: -0.33 · 95% CI -0.82 to 0.15
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0286 · Adjusted difference: -0.38 · 95% CI -0.73 to -0.03
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0274 · Adjusted difference: -0.38 · 95% CI -0.73 to -0.03
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.4981 · Adjusted difference: -0.28 · 95% CI -0.81 to 0.24
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0472 · Adjusted difference: -0.39 · 95% CI -0.78 to -0.00
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0753 · Adjusted difference: -0.36 · 95% CI -0.75 to 0.03
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.1853 · Adjusted difference: -0.43 · 95% CI -0.99 to 0.13
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0009 · Adjusted difference: -0.62 · 95% CI -1.03 to -0.21
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · ANCOVA · p = 0.0008 · Adjusted difference: -0.62 · 95% CI -1.03 to -0.21
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0005 · Adjusted difference: 0.41 · 95% CI 0.15 to 0.67
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0003 · Adjusted difference: 0.42 · 95% CI 0.16 to 0.68
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0060 · Adjusted difference: 0.39 · 95% CI 0.09 to 0.69
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0039 · Adjusted difference: 0.40 · 95% CI 0.10 to 0.70
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0007 · Adjusted difference: 0.53 · 95% CI 0.18 to 0.88
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0007 · Adjusted difference: 0.53 · 95% CI 0.19 to 0.88
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0450 · Adjusted difference: 0.39 · 95% CI 0.01 to 0.77
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.0259 · Adjusted difference: 0.42 · 95% CI 0.04 to 0.80
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.9881 · Adjusted difference: 0.06 · 95% CI -0.34 to 0.46
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · ANCOVA · p = 0.9891 · Adjusted difference: 0.06 · 95% CI -0.34 to 0.46
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.0463 · Adjusted difference: -0.29 · 95% CI -0.57 to -0.00
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.1867 · Adjusted difference: -0.23 · 95% CI -0.56 to 0.11
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.0213 · Adjusted difference: -0.44 · 95% CI -0.81 to -0.07
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.0003 · Adjusted difference: -0.78 · 95% CI -1.19 to -0.37
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · ANCOVA · p = 0.0002 · Adjusted difference: -0.82 · 95% CI -1.24 to -0.40
SecondaryPercentage of Participants With DAS Low Disease Activity

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. LDAS is defined as DAS28 ≤ 3.2

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Number · Percentage of participants
Percentage of Participants With DAS Low Disease Activity
Percentage of participantsCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 70.0 (0.00 to 0.00)0.9 (0.00 to 2.71)1.8 (0.00 to 4.31)0.0 (0.00 to 0.00)1.8 (0.00 to 4.28)2.1 (0.00 to 6.12)0.0 (0.00 to 0.00)
Week 2 day 140.0 (0.00 to 0.00)0.0 (0.00 to 0.00)1.8 (0.00 to 4.31)0.9 (0.00 to 2.68)4.5 (0.65 to 8.36)2.1 (0.00 to 6.12)2.0 (0.00 to 5.88)
Week 4 Day 280.0 (0.00 to 0.00)1.8 (0.00 to 4.35)6.4 (1.80 to 10.93)1.8 (0.00 to 4.31)11.7 (5.73 to 17.69)2.1 (0.00 to 6.12)0.0 (0.00 to 0.00)
Week 8 Day 560.0 (0.00 to 0.00)8.3 (3.09 to 13.42)11.8 (5.79 to 17.85)3.6 (0.14 to 7.13)18.0 (10.87 to 25.17)2.1 (0.00 to 6.12)2.0 (0.00 to 5.88)
Week 12 Day 847.5 (0.00 to 15.66)19.3 (11.86 to 26.67)14.5 (7.96 to 21.13)3.6 (0.14 to 7.13)17.1 (10.11 to 24.12)14.6 (4.60 to 24.57)4.0 (0.00 to 9.43)
Statistical analysis
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -6.06 to 6.06
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.5976 · Adjusted difference: 0.91 · 95% CI -2.48 to 4.30
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.3482 · Adjusted difference: 1.82 · 95% CI -1.98 to 5.62
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.8979 · Adjusted difference: -0.40 · 95% CI -6.51 to 5.71
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.5976 · Adjusted difference: -0.91 · 95% CI -4.30 to 2.48
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.6546 · Adjusted difference: 0.91 · 95% CI -3.07 to 4.89
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.7988 · Adjusted difference: -0.80 · 95% CI -6.95 to 5.35
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.9975 · Adjusted difference: 0.01 · 95% CI -4.35 to 4.36
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.1185 · Adjusted difference: 4.55 · 95% CI -1.16 to 10.25
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.4765 · Adjusted difference: -2.40 · 95% CI -9.01 to 4.21
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.1655 · Adjusted difference: 4.61 · 95% CI -1.90 to 11.12
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0234 · Adjusted difference: 8.18 · 95% CI 1.11 to 15.26
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.5490 · Adjusted difference: 3.20 · 95% CI -7.27 to 13.67
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0003 · Mean difference (net): 15.62 · 95% CI 7.22 to 24.03
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0044 · Adjusted difference: 10.91 · 95% CI 3.39 to 18.43
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.6588 · Adjusted difference: 2.05 · 95% CI -7.07 to 11.18
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.8853 · Adjusted difference: 0.68 · 95% CI -8.62 to 9.99
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.6564 · Adjusted difference: 2.05 · 95% CI -7.00 to 11.11
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.8853 · Adjusted difference: 0.68 · 95% CI -8.62 to 9.99
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.0584 · Adjusted difference: 11.64 · 95% CI -0.41 to 23.70
SecondaryPercentage of Participants With DAS Remission

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Number · Percentage of participants
Percentage of Participants With DAS Remission
Percentage of participantsCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 70.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)2.1 (0.00 to 6.12)0.0 (0.00 to 0.00)
Week 2 Day 140.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.9 (0.00 to 2.68)0.0 (0.00 to 0.00)0.9 (0.00 to 2.66)0.00 (0.00 to 0.00)0.0 (0.00 to 0.00)
Week 4 Day 280.0 (0.00 to 0.00)0.0 (0.00 to 0.00)1.8 (0.00 to 4.31)0.9 (0.00 to 2.68)4.5 (0.65 to 8.36)0.00 (0.00 to 0.00)0.0 (0.00 to 0.00)
Week 8 Day 560.0 (0.00 to 0.00)3.7 (0.14 to 7.20)4.5 (0.65 to 8.44)1.8 (0.00 to 4.31)9.0 (3.68 to 14.34)0.00 (0.00 to 0.00)0.0 (0.00 to 0.00)
Week 12 Day 842.5 (0.00 to 7.34)7.3 (2.44 to 12.24)8.2 (3.06 to 13.30)3.6 (0.14 to 7.13)9.0 (3.68 to 14.34)4.2 (0.00 to 9.82)4.0 (0.00 to 9.43)
Statistical analysis
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -6.06 to 6.06
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -2.92 to 2.92
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -2.91 to 2.91
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -6.06 to 6.06
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -2.92 to 2.92
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.5976 · Adjusted difference: 0.91 · 95% CI -2.47 to 4.28
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.8979 · Adjusted difference: -0.40 · 95% CI -6.51 to 5.71
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.5976 · Adjusted difference: -0.91 · 95% CI -4.30 to 2.48
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.6669 · Adjusted difference: 0.91 · 95% CI -3.23 to 5.05
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.6309 · Adjusted difference: -1.60 · 95% CI -8.13 to 4.93
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.4473 · Adjusted difference: 1.83 · 95% CI -2.90 to 6.56
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.3021 · Adjusted difference: 2.73 · 95% CI -2.45 to 7.91
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.7134 · Adjusted difference: -1.60 · 95% CI -10.14 to 6.94
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.2635 · Adjusted difference: 3.70 · 95% CI -2.79 to 10.19
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.1749 · Adjusted difference: 4.55 · 95% CI -2.02 to 11.11
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.6588 · Adjusted difference: 2.05 · 95% CI -7.07 to 11.18
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -8.31 to 8.31
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -8.31 to 8.31
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -8.31 to 8.31
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.7848 · Adjusted difference: 1.37 · 95% CI -8.46 to 11.20
SecondaryPercentage of Participants Meeting the Boolean-based Remission Criteria

Boolean Remission is defined as Tender joint count less than 1, Swollen joint count less than 1, CRP less than 1 mg/dL, patient global assessment less than 1 (on 0 to 10 VAS scale).

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting the Boolean-based Remission Criteria
Percentage of participantsCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 70.0 (0.00 to 0.00)0.9 (0.00 to 2.76)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)
Week 2 Day 140.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)
Week 4 Day 280.0 (0.00 to 0.00)1.0 (0.00 to 2.81)0.0 (0.00 to 0.00)0.9 (0.00 to 2.73)2.8 (0.00 to 5.82)2.1 (0.00 to 6.25)0.0 (0.00 to 0.00)
Week 8 Day 560.0 (0.00 to 0.00)2.0 (0.00 to 4.70)1.90 (0.00 to 4.56)1.0 (0.00 to 2.86)3.7 (0.14 to 7.20)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)
Week 12 Day 840.0 (0.00 to 0.00)2.0 (0.00 to 4.84)4.1 (0.17 to 8.08)1.0 (0.00 to 2.89)6.5 (1.84 to 11.12)8.5 (0.53 to 16.49)0.0 (0.00 to 6.53)
Statistical analysis
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -6.28 to 6.28
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.5941 · Adjusted difference: 0.93 · 95% CI -2.50 to 4.37
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -2.93 to 2.93
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -6.17 to 6.17
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -2.95 to 2.95
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -2.92 to 2.92
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.8929 · Adjusted difference: -0.43 · 95% CI -6.62 to 5.77
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.9424 · Adjusted difference: -0.13 · 95% CI -3.78 to 3.51
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.5927 · Adjusted difference: -0.94 · 95% CI -4.40 to 2.51
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.8788 · Adjusted difference: -0.46 · 95% CI -6.31 to 5.40
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.6876 · Adjusted difference: 0.87 · 95% CI -3.36 to 5.09
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.6656 · Adjusted difference: 0.97 · 95% CI -3.42 to 5.35
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.8787 · Adjusted difference: -0.46 · 95% CI -6.34 to 5.42
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.7101 · Adjusted difference: 0.74 · 95% CI -3.17 to 4.66
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.2425 · Adjusted difference: 3.20 · 95% CI -2.16 to 8.55
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -8.68 to 8.68
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -8.39 to 8.39
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.6658 · Adjusted difference: 2.03 · 95% CI -7.17 to 11.22
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -8.77 to 8.77
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.2457 · Adjusted difference: 6.57 · 95% CI -4.52 to 17.66
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI)

CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest. Negative values indicate improvement/reduction in RA disease activity.

Time frame:
Baseline, Days 7, 14, 28, 56 and 84
Reported as:
Mean · Score on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI)
Score on a scaleCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 7-5.45 ± 7.69-6.70 ± 8.26-7.40 ± 9.97-4.71 ± 12.91-9.64 ± 8.93-8.61 ± 10.67-5.26 ± 9.79
Week 2 Day 14-6.85 ± 11.10-10.33 ± 10.45-11.33 ± 10.47-7.44 ± 13.39-13.44 ± 10.52-9.64 ± 12.17-7.70 ± 10.64
Week 4 Day 28-10.36 ± 10.88-13.84 ± 12.11-13.78 ± 11.46-9.43 ± 14.77-17.74 ± 10.84-11.83 ± 11.08-7.49 ± 11.46
Week 8 Day 56-14.76 ± 10.04-18.61 ± 13.48-18.10 ± 12.99-15.49 ± 15.74-21.36 ± 11.69-17.38 ± 12.39-7.57 ± 10.51
Week 12 Day 84-16.99 ± 11.21-22.05 ± 12.19-22.10 ± 11.83-17.02 ± 16.24-22.22 ± 11.76-20.42 ± 13.20-12.23 ± 12.06
Statistical analysis
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.4960 · Adjusted difference: -2.36 · 95% CI -6.73 to 2.02
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.2736 · Adjusted difference: -2.18 · 95% CI -5.34 to 0.98
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0608 · Adjusted difference: -3.08 · 95% CI -6.26 to 0.10
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.9237 · Adjusted difference: -1.25 · 95% CI -6.02 to 3.52
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0893 · Adjusted difference: -3.14 · 95% CI -6.60 to 0.33
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0138 · Adjusted difference: -4.07 · 95% CI -7.51 to -0.63
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.3358 · Adjusted difference: -3.22 · 95% CI -8.24 to 1.80
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0078 · Adjusted difference: -4.57 · 95% CI -8.20 to -0.94
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0059 · Adjusted difference: -4.68 · 95% CI -8.30 to -1.06
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.6503 · Adjusted difference: -2.29 · 95% CI -7.39 to 2.80
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.1282 · Adjusted difference: -3.12 · 95% CI -6.84 to 0.59
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.1675 · Adjusted difference: -2.94 · 95% CI -6.65 to 0.78
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.4220 · Adjusted difference: -2.94 · 95% CI -7.96 to 2.09
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0027 · Adjusted difference: -5.10 · 95% CI -8.77 to -1.42
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0011 · Adjusted difference: -5.47 · 95% CI -9.15 to -1.78
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.0455 · Adjusted difference: 3.21 · 95% CI 0.05 to 6.37
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.2309 · Adjusted difference: 2.31 · 95% CI -0.87 to 5.48
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.0698 · Adjusted difference: 3.27 · 95% CI -0.18 to 6.72
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.2851 · Adjusted difference: 2.33 · 95% CI -1.09 to 5.76
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.0131 · Adjusted difference: 4.29 · 95% CI 0.69 to 7.90
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.0161 · Adjusted difference: 4.18 · 95% CI 0.59 to 7.78
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.0360 · Adjusted difference: 3.85 · 95% CI 0.18 to 7.51
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.0252 · Adjusted difference: 4.04 · 95% CI 0.37 to 7.70
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.9032 · Adjusted difference: 1.03 · 95% CI -2.59 to 4.66
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.9791 · Adjusted difference: 0.66 · 95% CI -2.97 to 4.30
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.0927 · Adjusted difference: -3.22 · 95% CI -6.98 to 0.54
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.3202 · Adjusted difference: -2.12 · 95% CI -6.33 to 2.09
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.0476 · Adjusted difference: -4.20 · 95% CI -8.36 to -0.04
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted difference: -9.93 · 95% CI -14.31 to -5.55
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.0003 · Adjusted difference: -8.23 · 95% CI -12.56 to -3.90
SecondaryPercentage of Participants Meeting the CDAI-based Remission Criteria

Clinical Disease Activity Index is defined as CDAI= : SJC(28) + TJC(28) + PGA + MDG where TJC and SJC are the tender and swollen joint counts from 28 joints, PGA is the patient's global assessment of disease activity (on a 0-10 scale) and MDG is physician global assessment of disease activity (on a 0-10 scale). The cutoff value for CDAI remission is \<=2.8.

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting the CDAI-based Remission Criteria
Percentage of participantsCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 70.0 (0.00 to 0.00)0.9 (0.00 to 2.71)0.9 (0.00 to 2.68)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)
Week 2 Day 140.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)1.8 (0.00 to 4.28)0.0 (0.00 to 0.00)0.0 (0.00 to 0.00)
Week 4 Day 280.0 (0.00 to 0.00)0.9 (0.00 to 2.71)0.9 (0.00 to 2.68)0.0 (0.00 to 0.00)4.5 (0.65 to 8.36)2.1 (0.00 to 6.12)0.0 (0.00 to 0.00)
Week 8 Day 560.0 (0.00 to 0.00)2.8 (0.00 to 5.82)5.5 (1.21 to 9.70)0.00 (0.00 to 0.00)7.2 (2.40 to 12.02)4.2 (0.00 to 9.82)0.0 (0.00 to 0.00)
Week 12 Day 840.0 (0.00 to 0.00)5.5 (1.22 to 9.79)6.4 (1.80 to 10.93)0.9 (0.00 to 2.68)9.9 (4.35 to 15.47)6.3 (0.00 to 13.10)6.0 (0.00 to 12.58)
Statistical analysis
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -6.06 to 6.06
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.5976 · Adjusted difference: 0.91 · 95% CI -2.48 to 4.30
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.5976 · Adjusted difference: 0.91 · 95% CI -2.47 to 4.28
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -6.06 to 6.06
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -2.92 to 2.92
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -2.91 to 2.91
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -6.06 to 6.06
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.5726 · Adjusted difference: 0.91 · 95% CI -2.26 to 4.09
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.5976 · Adjusted difference: 0.91 · 95% CI -2.47 to 4.28
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -6.06 to 6.06
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.1446 · Adjusted difference: 2.74 · 95% CI -0.94 to 6.42
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0286 · Adjusted difference: 5.45 · 95% CI 0.57 to 10.34
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.8979 · Adjusted difference: -0.40 · 95% CI -6.51 to 5.71
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0708 · Adjusted difference: 4.57 · 95% CI -0.39 to 9.52
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0478 · Adjusted difference: 5.45 · 95% CI 0.05 to 10.86
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -8.31 to 8.31
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -8.31 to 8.31
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.6564 · Adjusted difference: 2.05 · 95% CI -7.00 to 11.11
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.3838 · Adjusted difference: 4.11 · 95% CI -5.14 to 13.36
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.9009 · Adjusted difference: 0.68 · 95% CI -10.10 to 11.47
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI)

Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =\< 3.3 indicates disease remission, \> 3.4 to 11 indicates low disease activity, \> 11 to 26 indicates moderate disease activity, and \> 26 indicates high disease activity

Time frame:
Baseline, Days 7, 14, 28, 56 and 84
Reported as:
Mean · Score on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI)
Score on a scaleCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 7-5.36 ± 7.86-6.48 ± 8.87-6.99 ± 10.49-4.75 ± 13.25-10.86 ± 9.33-8.73 ± 11.21-5.37 ± 9.49
Week 2 Day 14-6.50 ± 10.54-10.46 ± 10.97-11.44 ± 10.85-7.54 ± 13.74-14.39 ± 10.99-9.84 ± 12.29-8.13 ± 11.01
Week 4 Day 28-10.53 ± 11.03-14.47 ± 12.41-14.21 ± 12.20-8.92 ± 15.17-18.87 ± 11.20-12.13 ± 11.13-7.74 ± 12.02
Week 8 Day 56-15.25 ± 10.41-18.95 ± 13.80-18.97 ± 13.91-15.74 ± 16.18-22.62 ± 11.97-18.57 ± 12.80-7.82 ± 11.20
Week 12 Day 84-17.54 ± 11.36-22.89 ± 12.52-23.24 ± 12.50-17.47 ± 16.70-23.33 ± 11.97-21.97 ± 13.78-12.92 ± 12.61
Statistical analysis
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.5455 · Adjusted difference: -2.36 · 95% CI -7.00 to 2.27
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.4114 · Adjusted difference: -1.97 · 95% CI -5.30 to 1.36
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.1739 · Adjusted difference: -2.62 · 95% CI -5.97 to 0.72
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.9761 · Adjusted difference: -0.94 · 95% CI -5.93 to 4.06
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0998 · Adjusted difference: -3.18 · 95% CI -6.78 to 0.41
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0239 · Adjusted difference: -3.97 · 95% CI -7.54 to -0.39
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.2018 · Adjusted difference: -3.98 · 95% CI -9.25 to 1.30
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0011 · Adjusted difference: -5.67 · 95% CI -9.48 to -1.87
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0026 · Adjusted difference: -5.27 · 95% CI -9.06 to -1.48
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.6336 · Adjusted difference: -2.47 · 95% CI -7.84 to 2.90
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0950 · Adjusted difference: -3.49 · 95% CI -7.38 to 0.41
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.1451 · Adjusted difference: -3.18 · 95% CI -7.06 to 0.71
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.3434 · Adjusted difference: -3.28 · 95% CI -8.43 to 1.87
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0016 · Adjusted difference: -5.45 · 95% CI -9.23 to -1.68
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0006 · Adjusted difference: -5.88 · 95% CI -9.65 to -2.10
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.0025 · Adjusted difference: 4.64 · 95% CI 1.31 to 7.96
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.0129 · Adjusted difference: 3.98 · 95% CI 0.64 to 7.32
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.0206 · Adjusted difference: 4.04 · 95% CI 0.46 to 7.62
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.0841 · Adjusted difference: 3.26 · 95% CI -0.30 to 6.82
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.0088 · Adjusted difference: 4.67 · 95% CI 0.91 to 8.42
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.0034 · Adjusted difference: 5.07 · 95% CI 1.34 to 8.81
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.0138 · Adjusted difference: 4.55 · 95% CI 0.71 to 8.39
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.0073 · Adjusted difference: 4.85 · 95% CI 1.02 to 8.69
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.8284 · Adjusted difference: 1.29 · 95% CI -2.46 to 5.03
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab · Cochran-Mantel-Haenszel · p = 0.9525 · Adjusted difference: 0.86 · 95% CI -2.88 to 4.60
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.0856 · Adjusted difference: -3.22 · 95% CI -6.91 to 0.46
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.3374 · Adjusted difference: -2.08 · 95% CI -6.36 to 2.20
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.0534 · Adjusted difference: -4.24 · 95% CI -8.53 to 0.06
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted difference: -10.8 · 95% CI -15.33 to -6.32
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted difference: -9.22 · 95% CI -13.63 to -4.81
SecondaryPercentage of Participants Meeting the SDAI-based Remission Criteria

The SDAI was the numerical sum of five outcome parameter: SJC and TJC (based on a 28-joint assessment), PGA and MDG (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. The SDAI =\< 3.3 indicates disease remission

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting the SDAI-based Remission Criteria
Percentage of participantsCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 70.00 (0.00 to 0.00)0.9 (0.00 to 2.71)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 2 Day 140.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)1.8 (0.00 to 4.28)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 4 Day 280.00 (0.00 to 0.00)0.9 (0.00 to 2.71)0.9 (0.00 to 2.68)0.00 (0.00 to 0.00)4.5 (0.65 to 8.36)2.1 (0.00 to 6.12)0.00 (0.00 to 0.00)
Week 8 Day 560.00 (0.00 to 0.00)2.8 (0.00 to 5.82)3.6 (0.14 to 7.13)0.00 (0.00 to 0.00)6.3 (1.78 to 10.83)0.00 (0.00 to 0.00)0.00 (0.00 to 0.00)
Week 12 Day 840.00 (0.00 to 0.00)4.6 (0.66 to 8.51)6.4 (1.80 to 10.93)0.9 (0.00 to 2.68)9.0 (3.68 to 14.34)6.3 (0.00 to 13.10)6.0 (0.00 to 12.58)
Statistical analysis
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -6.06 to 6.06
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.5976 · Adjusted difference: 0.91 · 95% CI -2.48 to 4.30
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -2.91 to 2.91
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -6.06 to 6.06
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -2.92 to 2.92
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -2.91 to 2.91
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -6.06 to 6.06
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.5726 · Adjusted difference: 0.91 · 95% CI -2.26 to 4.09
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.5976 · Mean difference (net): 0.91 · 95% CI -2.47 to 4.28
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -6.06 to 6.06
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.1446 · Adjusted difference: 2.74 · 95% CI -0.94 to 6.42
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.1050 · Adjusted difference: 3.64 · 95% CI -0.76 to 8.03
  • Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.8979 · Adjusted difference: -0.40 · 95% CI -6.51 to 5.71
  • Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.1270 · Adjusted difference: 3.65 · 95% CI -1.04 to 8.35
  • Cohort 1: GDC-0853 High Dose + Adalimumab Placebo vs Cohort 1: GDC-0853 Placebo + Adalimumab Placebo · Cochran-Mantel-Haenszel · p = 0.0501 · Adjusted difference: 5.45 · 95% CI -0.00 to 10.91
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -8.31 to 8.31
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -8.31 to 8.31
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.6564 · Adjusted difference: 2.05 · 95% CI -7.00 to 11.11
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 1.0000 · Adjusted difference: 0.00 · 95% CI -8.31 to 8.31
  • Cohort 2: GDC-0853 High Dose vs Cohort 2: GDC-0853 Placebo · Cochran-Mantel-Haenszel · p = 0.9051 · Adjusted difference: 0.68 · 95% CI -10.58 to 11.95
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Version 2.0 (V2) Scores for Physical and Mental Components

The 36-Item Short Form Health Survey (SF-36v2) is a questionnaire used to assess functional health and well-being and consists of eight domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. The SF-36v2 is summarized into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. The PCS and MCS scores range from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.

Time frame:
Day 84
Reported as:
Mean · Number on a scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Version 2.0 (V2) Scores for Physical and Mental Components
Number on a scaleCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Physical component score change: baseline-week 125.57 ± 5.985.71 ± 6.856.59 ± 7.543.54 ± 6.816.41 ± 6.435.35 ± 7.481.75 ± 6.39
Mental component score change: baseline-week 127.04 ± 9.324.89 ± 10.576.92 ± 12.064.29 ± 10.516.50 ± 10.795.76 ± 10.225.11 ± 10.10
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score

The FACIT-Fatigue Scale consists of 13 items designed to measure the degree of fatigue experienced by the patient in the previous 7 days. For each question, there are five possible responses: 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much). A total fatigue score is calculated by summing all items, and possible total scores range from 0 (maximum fatigue) to 52 (no fatigue). A positive change from baseline indicates an improvement in the patient's fatigue (less fatigue).

Time frame:
Day 84
Reported as:
Mean · Score on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score
Score on a scaleCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score9.00 ± 10.578.21 ± 10.228.95 ± 10.047.08 ± 10.889.59 ± 9.028.85 ± 9.575.71 ± 9.24
SecondaryChange From Baseline in Tender/Painful Joint Count (68 Joint Count)

Tender Joint Count: a total of 68 joints will be assessed for tenderness. Each joint is assessed for the presence/absence of tenderness. 68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Mean · Score on a scale
Change From Baseline in Tender/Painful Joint Count (68 Joint Count)
Score on a scaleCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 7-2.79 ± 7.25-4.12 ± 8.14-3.33 ± 9.27-3.81 ± 10.85-5.58 ± 9.41-6.57 ± 8.66-3.06 ± 11.01
Week 2 Day 19-4.33 ± 12.31-6.36 ± 10.88-5.91 ± 9.38-5.78 ± 11.50-8.62 ± 10.46-6.08 ± 8.53-3.92 ± 10.77
Week 4 Day 28-6.00 ± 8.89-7.90 ± 11.28-6.84 ± 9.53-7.55 ± 12.97-11.61 ± 11.43-7.79 ± 7.93-4.40 ± 12.37
Week 8 Day 56-9.72 ± 8.20-11.57 ± 12.18-9.75 ± 10.93-10.75 ± 14.37-14.12 ± 11.33-11.65 ± 10.34-4.60 ± 12.41
Week 12 Day 84-10.33 ± 9.40-12.72 ± 12.05-11.49 ± 11.15-10.55 ± 14.37-15.49 ± 12.31-13.73 ± 12.81-7.14 ± 13.32
SecondaryChange From Baseline in Swollen Joint Count (66 Joint Count)

Swollen Joint Count: a total of 66 joints will be assessed for swelling. Each joint is assessed for the presence/absence of swelling. 66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Mean · Score on a scale
Change From Baseline in Swollen Joint Count (66 Joint Count)
Score on a scaleCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 7-1.84 ± 5.19-2.89 ± 5.01-3.45 ± 6.02-3.35 ± 9.38-3.94 ± 5.33-3.45 ± 4.90-1.49 ± 4.49
Week 2 Day 14-3.95 ± 6.44-4.78 ± 5.99-5.06 ± 5.14-4.23 ± 9.88-6.26 ± 5.98-3.29 ± 5.69-2.96 ± 6.27
Week 4 Day 28-4.38 ± 4.55-6.33 ± 7.98-5.95 ± 6.09-5.47 ± 9.26-8.50 ± 6.39-4.21 ± 6.39-3.46 ± 5.62
Week 8 Day 56-6.54 ± 5.78-8.06 ± 8.13-7.72 ± 7.44-7.41 ± 10.82-9.60 ± 6.94-6.81 ± 6.16-3.02 ± 7.76
Week 12 Day 84-7.36 ± 5.88-8.89 ± 8.23-8.48 ± 7.01-8.26 ± 11.48-9.94 ± 6.91-7.65 ± 6.75-4.86 ± 5.84
SecondaryChange From Baseline in Patient Assessment Score of Arthritis Pain

Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Mean · Score on a scale
Change From Baseline in Patient Assessment Score of Arthritis Pain
Score on a scaleCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 7-9.00 ± 18.66-9.20 ± 20.56-11.18 ± 21.64-4.12 ± 22.43-15.75 ± 18.71-11.94 ± 21.25-2.76 ± 18.24
Week 2 Day 14-6.08 ± 21.64-12.16 ± 20.09-17.08 ± 23.46-8.22 ± 25.72-18.13 ± 17.71-15.08 ± 21.87-4.72 ± 17.64
Week 4 Day 28-13.41 ± 16.79-15.75 ± 21.97-18.63 ± 24.87-10.08 ± 27.16-20.21 ± 21.97-16.64 ± 27.86-7.54 ± 23.80
Week 8 Day 56-18.38 ± 19.35-23.21 ± 22.10-25.95 ± 27.50-16.37 ± 27.65-24.70 ± 22.23-21.21 ± 27.13-7.13 ± 25.73
Week 12 Day 84-23.14 ± 21.14-26.48 ± 23.30-30.63 ± 28.49-17.88 ± 29.42-26.30 ± 23.87-26.49 ± 27.65-13.98 ± 25.32
SecondaryChange From Baseline in Patient Global Assessment Score of Arthritis Pain

Participant-assessed arthritis pain was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of arthritis pain (0 mm=none; 100 mm=very severe). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change indicated a decrease in participant-assessed arthritis pain.

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Mean · Score on a scale
Change From Baseline in Patient Global Assessment Score of Arthritis Pain
Score on a scaleCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 7-9.00 ± 15.88-10.30 ± 20.82-11.82 ± 22.52-3.07 ± 20.83-18.33 ± 20.81-13.15 ± 22.17-4.96 ± 19.18
Week 2 Day 14-5.50 ± 20.98-13.70 ± 19.63-14.84 ± 24.08-5.39 ± 26.13-18.94 ± 22.33-15.46 ± 21.67-8.64 ± 19.43
Week 4 Day 28-12.11 ± 16.6816.10 ± 23.48-17.75 ± 22.73-6.36 ± 25.99-21.78 ± 25.53-18.26 ± 27.53-10.96 ± 21.54
Week 8 Day 56-19.19 ± 16.88-24.06 ± 24.99-22.59 ± 26.81-14.19 ± 29.80-26.77 ± 25.69-21.17 ± 25.98-11.82 ± 21.66
Week 12 Day 84-23.33 ± 22.03-26.67 ± 26.89-27.33 ± 27.33-16.87 ± 28.68-26.24 ± 27.02-25.55 ± 27.52-13.80 ± 22.17
SecondaryChange From Baseline in Physician's Global Assessment Score of Arthritis

Physician's assessment of participant's disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the physician's assessment of the participant's disease activity (0 mm=very good; 100 mm=very poor). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change from baseline indicated an improvement in physician-assessed disease activity.

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Mean · Score on a scale
Change From Baseline in Physician's Global Assessment Score of Arthritis
Score on a scaleCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 7-7.89 ± 13.16-10.68 ± 15.41-12.82 ± 17.03-5.85 ± 15.44-14.23 ± 16.13-9.57 ± 17.10-7.66 ± 18.33
Week 2 Day 14-11.10 ± 15.65-15.86 ± 16.77-18.30 ± 19.04-9.01 ± 18.07-21.33 ± 19.61-14.23 ± 18.50-9.85 ± 17.55
Week 4 Day 28-16.89 ± 19.06-22.02 ± 18.61-20.92 ± 17.71-14.01 ± 21.03-28.81 ± 19.34-17.70 ± 20.49-12.73 ± 20.42
Week 8 Day 56-24.59 ± 15.06-28.52 ± 21.11-29.67 ± 20.01-20.87 ± 23.85-36.16 ± 21.82-22.40 ± 20.43-9.91 ± 19.67
Week 12 Day 84-26.81 ± 16.20-32.43 ± 19.24-34.48 ± 19.49-23.19 ± 23.39-37.18 ± 21.02-30.82 ± 21.95-18.44 ± 21.86
SecondaryChange From Baseline in C-Reactive Protein (CRP) Levels

C-reactive protein is a biological marker of inflammation and is measured in nanograms per milliliter (ng/mL)

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Mean · (ng/mL) nanograms per milliliter
Change From Baseline in C-Reactive Protein (CRP) Levels
(ng/mL) nanograms per milliliterCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 70.14 ± 2.090.30 ± 2.580.22 ± 2.490.01 ± 1.29-1.21 ± 2.37-0.12 ± 2.60-0.10 ± 1.76
Week 2 Day 140.27 ± 1.78-0.10 ± 1.92-0.21 ± 2.29-0.12 ± 1.53-0.93 ± 2.70-0.20 ± 2.38-0.25 ± 2.60
Week 4 Day 280.15 ± 2.45-0.25 ± 2.55-0.44 ± 2.300.14 ± 2.00-1.11 ± 2.17-0.30 ± 2.58-0.24 ± 2.80
Week 8 Day 56-0.49 ± 1.66-0.52 ± 1.83-0.89 ± 3.16-0.39 ± 1.64-1.14 ± 2.39-1.19 ± 2.18-0.26 ± 2.55
Week 12 Day 84-0.59 ± 1.43-0.77 ± 1.89-1.30 ± 2.88-0.45 ± 1.71-1.03 ± 2.01-1.55 ± 2.35-0.56 ± 2.75
SecondaryChange From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

The Stanford Health Assessment Questionnaire disability index is a patient-reported outcome used to assess difficulty in performing activities of daily living. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. To respond to each question, a four-level response with higher scores showing larger functional limitations, was chosen. Scoring is as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. The composite HAQ-DI score is the mean of the eight domain scores and the score ranges from 0 (no functional impairment) to 3 (maximum functional impairment). A negative change from baseline indicates improvement.

Time frame:
Days 7, 14, 28, 56, and 84
Reported as:
Mean · Score on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
Score on a scaleCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
Week 1 Day 7-0.20 ± 0.37-0.15 ± 0.35-0.22 ± 0.48-0.10 ± 0.38-0.26 ± 0.42-0.19 ± 0.36-0.14 ± 0.46
Week 2 Day 14-0.24 ± 0.39-0.23 ± 0.46-0.28 ± 0.50-0.17 ± 0.45-0.35 ± 0.47-0.23 ± 0.45-0.13 ± 0.49
Week 4 Day 28-0.34 ± 0.47-0.32 ± 0.48-0.40 ± 0.50-0.19 ± 0.56-0.50 ± 0.50-0.23 ± 0.42-0.17 ± 0.44
Week 8 Day 56-0.49 ± 0.47-0.44 ± 0.56-0.56 ± 0.55-0.40 ± 0.64-0.60 ± 0.55-0.45 ± 0.50-0.23 ± 0.55
Week 12 Day 84-0.51 ± 0.57-0.57 ± 0.57-0.65 ± 0.60-0.35 ± 0.68-0.65 ± 0.61-0.53 ± 0.61-0.30 ± 0.62
SecondaryArea Under the Concentration Time Curve From Time 0 to Time 24 of GDC-0853 at Steady State (AUC0-24,ss)

The Pharmacokinetics (PK) evaluation may include, but will not be limited to, plasma GDC-0853 concentrations and population PK model estimated PK exposures (area under the plasma concentration-time curve \[AUC\]. AUC was measured in Nanograms(ng) per millilitre(mL)\*hour (hr)

Time frame:
Pre-dose (0 hours) up to 10 hours post-dose on Day 28
Reported as:
Mean · Ng/mL*(hr)
Area Under the Concentration Time Curve From Time 0 to Time 24 of GDC-0853 at Steady State (AUC0-24,ss)
Ng/mL*(hr)Cohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 2: GDC-0853 High Dose
Area Under the Concentration Time Curve From Time 0 to Time 24 of GDC-0853 at Steady State (AUC0-24,ss)1170 ± 16002910 ± 31809380 ± 48609890 ± 5480
SecondaryMaximum Observed Plasma Concentration of GDC-0853 at Steady State (Cmax,ss)

Cmax is the maximum (peak) plasma concentration over the dosing interval at steady state (ss)

Time frame:
Pre-dose (0 hours) up to 10 hours post-dose on Day 28
Reported as:
Mean · Nanogram per Milliliter (ng/mL)
Maximum Observed Plasma Concentration of GDC-0853 at Steady State (Cmax,ss)
Nanogram per Milliliter (ng/mL)Cohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 2: GDC-0853 High Dose
Maximum Observed Plasma Concentration of GDC-0853 at Steady State (Cmax,ss)110 ± 116280 ± 223591 ± 282621 ± 302
SecondaryMinimum Observed Plasma Concentration of GDC-0853 at Steady State (Cmin,ss)

Cmin is the minimum concentration over the dosing interval at steady state (ss)

Time frame:
Pre-dose (0 hours) up to 10 hours post-dose on Day 28
Reported as:
Mean · Nanogram per Milliliter (ng/mL)
Minimum Observed Plasma Concentration of GDC-0853 at Steady State (Cmin,ss)
Nanogram per Milliliter (ng/mL)Cohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 2: GDC-0853 High Dose
Minimum Observed Plasma Concentration of GDC-0853 at Steady State (Cmin,ss)22.4 ± 41.054.7 ± 83.4250 ± 146263 ± 170

Adverse events

Collected over From randomization to end of study (approximately 22 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo0/40 (0%)0/40 (0%)9/40 (22.5%)
Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo0/109 (0%)1/109 (0.9%)18/109 (16.5%)
Cohort 1: GDC-0853 High Dose + Adalimumab Placebo1/110 (0.9%)3/110 (2.7%)11/110 (10%)
Cohort 1: GDC-0853 Placebo + Adalimumab Placebo0/110 (0%)1/110 (0.9%)15/110 (13.6%)
Cohort 1: GDC-0853 Placebo + Adalimumab0/111 (0%)2/111 (1.8%)16/111 (14.4%)
Cohort 2: GDC-0853 High Dose0/49 (0%)0/49 (0%)3/49 (6.1%)
Cohort 2: GDC-0853 Placebo0/49 (0%)0/49 (0%)7/49 (14.3%)
Most frequent serious events
Most frequent serious events
EventCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
PNEUMONIAInfections and infestations0/401/1090/1101/1100/1110/490/49
MYOCARDIAL INFARCTIONCardiac disorders0/400/1091/1100/1100/111——
CELLULITSInfections and infestations0/400/1091/1100/1100/1110/490/49
PYELONEPHRITIS OBSTRUCTIONInfections and infestations0/400/1091/1100/1100/1110/490/49
CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders0/400/1090/1101/1100/1110/490/49
PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders0/400/1090/1101/1100/1110/490/49
SMALL INTESTINAL DISORDERSGastrointestinal disorders0/400/1090/1100/1101/1110/490/49
SEIZURENervous system disorders0/400/1090/1100/1101/1110/490/49
Most frequent other events
Most frequent other events
EventCohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 Placebo
URINARY TRACT INFECTIONInfections and infestations2/402/1090/1102/1108/1110/493/49
NAUSEAGastrointestinal disorders2/405/1093/1105/1101/1113/491/49
ANXIETYPsychiatric disorders0/400/1090/1100/1100/1110/493/49
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations1/403/1093/1102/1106/1110/490/49
VOMITINGGastrointestinal disorders2/401/1090/1100/1101/1110/490/49
ALANINE AMINOTRANFERASE INCREASEDInvestigations2/405/1094/1101/1101/1110/490/49
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations2/404/1093/1101/1101/1110/490/49
HEADACHENervous system disorders2/404/1095/1105/1100/1110/490/49

Baseline characteristics

Safety population (SAF) included all subjects that received treatment.

Age, Categorical
Age, Categorical(Participants)Cohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 PlaceboTotal
<=18 years00000000
Between 18 and 65 years35959998984140506
>=65 years5141112138972
Age, Continuous
Age, Continuous(Years)Cohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 PlaceboTotal
Mean52.3 ± 12.050.4 ± 11.049.9 ± 12.450.2 ± 11.649.9 ± 12.451.3 ± 13.254.6 ± 11.550.7 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 PlaceboTotal
Female35928590873737463
Male5172520241212115
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 PlaceboTotal
American Indian or Alaska native08121196551
Asian10000001
Black of African American012311210
White36969695994242506
Multiple32011007
Unknown02001003
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: GDC-0853 Low Dose + Adalimumab PlaceboCohort 1: GDC-0853 Mid Dose + Adalimumab PlaceboCohort 1: GDC-0853 High Dose + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + Adalimumab PlaceboCohort 1: GDC-0853 Placebo + AdalimumabCohort 2: GDC-0853 High DoseCohort 2: GDC-0853 PlaceboTotal
Hispanic or Latino8384038391715195
Not Hispanic or Latino31686972703233375
Not Stated01100013
Unknown12002005
08

Study locations

150 sites
  • Pinnacle Research Group; Llc, Central
    Anniston, Alabama 36207, United States
  • Arizona Arthritis & Rheumatology Associates, P.C.
    Glendale, Arizona 85306, United States
  • Medvin Clinical Research
    Covina, California 91723, United States
  • TriWest Research Associates, LLC
    El Cajon, California 92020, United States
  • Saint Jude Heritage Medical Grp
    Fullerton, California 92835, United States
  • Stanford University School of Medicine
    Stanford, California 94305-5151, United States
  • RASF-Clinical Research Center
    Boca Raton, Florida 33486, United States
  • ZASA Clinical Research
    Boynton Beach, Florida 33472, United States
  • Clinical Research of West Florida
    Clearwater, Florida 33765, United States
  • InVentiv Health
    Miami, Florida 33136, United States
  • Omega Research Consultants
    Orlando, Florida 32810, United States
  • McIlwain Medical Group
    Tampa, Florida 33613, United States
  • Institute of Arthritis Research
    Idaho Falls, Idaho 83404, United States
  • Advanced Clinical Research
    Meridian, Idaho 83642, United States
  • Medication Management
    Greensboro, North Carolina 27408, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Clinical Research Center of Reading
    Wyomissing, Pennsylvania 19610, United States
  • Metroplex Clinical Research
    Dallas, Texas 75231, United States
  • Baylor Research Inst.
    Dallas, Texas 75246, United States
  • Accurate Clinical Management - VO
    Houston, Texas 77004, United States
  • Accurate Clinical Research
    Houston, Texas 77089, United States
  • Crossroads Clinical Research, LLC
    Victoria, Texas 77901, United States
  • Danville Orthopedic Clinic, Inc.; Research Department
    Danville, Virginia 24541, United States
  • Instituto de Investigaciones Clinicas-Mar del Plata
    Buenos Aires, B7600FZN, Argentina
  • Organizacion Medica de Investigacion
    Buenos Aires, C1015ABO, Argentina
  • Hospital Italiano
    Buenos Aires, C1181ACH, Argentina
  • APRILLUS
    Buenos Aires, C1194AAO, Argentina
  • Instituto centenario
    Buenos Aires, C1204AAD, Argentina
  • Centro de Investigacion en Enfermedades Reumaticas CIER
    Ciudad Autonoma Buenos Aires, C1055AAF, Argentina
  • Expertia S.A- Mautalen Salud e Investigación
    Ciudad Autonoma Buenos Aires, C1128AAE, Argentina
  • CCBR - Buenos Aires - AR; AxisMed SRL
    Ciudad Autonoma Buenos Aires, C1430CKE, Argentina
  • ILAIM-CEOM Inst. Latinoamericano de Inv. Medicas
    Cordoba, X5000BNB, Argentina
  • Hospital Italiano de La Plata
    La Plata, 1900, Argentina
  • Centro de Investigaciones Medicas Mar Del Plata
    Mar del Plata, B7600DHK, Argentina
  • Instituto de Investigaciones Clínicas Quilmes
    Quilmes, 1878, Argentina
  • CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica
    San Juan, 5400, Argentina
  • Centro Medico Privado de Reumatologia; Reumathology
    San Miguel, T4000AXL, Argentina
  • CIP - Centro Internacional de Pesquisa; Pesquisa Clinica
    Goiânia, GO 74110-120, Brazil
  • Centro Mineiro de Pesquisa - CMIP
    Juiz de Fora, MG 36036-330, Brazil
  • Edumed - Educação e Saúde SA
    Curitiba, PR 80440-080, Brazil
  • Centro de Estudos em Terapias Inovadoras - CETI
    Curtiba, PR 80030-110, Brazil
  • CCBR - Synarc Centro de Pesquisa Clinica - RJ
    Rio de Janeiro, RJ 22271-100, Brazil
  • Hospital Sao Vicente de Paulo
    Passo Fundo, RS 99010-090, Brazil
  • LMK Serviços Médicos S/S
    Porto Alegre, RS 90480-000, Brazil
  • CAEP - Centro Avancado de Estudos e Pesquisas Ltda.
    Campinas, SP 13087-567, Brazil
  • Faculdade de Medicina do ABC - FMABC
    Santo Andre, SP 09060-650, Brazil
  • Instituto de Pesquisa Clínica e Medicina Avançada Ltda
    Sao Paulo, SP 05437-010, Brazil
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto
    São José do Rio Preto, SP 15090-000, Brazil
  • CPCLIN - Centro de Pesquisas Clínicas Ltda.; Pesquisa Clinica
    São Paulo, SP 01244-030, Brazil
  • MHAT - Dobrich, AD
    Dobrich, 9300, Bulgaria
  • MHAT "Eurohospital" - Plovdiv, OOD
    Plovdiv, 4002, Bulgaria
  • MHAT Kaspela; EOOD
    Plovdiv, 4002, Bulgaria
  • MHAT - Ruse, AD
    Ruse, 7002, Bulgaria
  • Medizinski Zentrar-1-Sevlievo EOOD
    Sevlievo, 5400, Bulgaria
  • MHAT "Hadzhi Dimitar", OOD
    Sliven, 8800, Bulgaria
  • Medical Center Excelsior OOD
    Sofia, 1000, Bulgaria
  • NMTH "Tsar Boris III"
    Sofia, 1233, Bulgaria
  • MHAT "Lyulin", EAD
    Sofia, 1336, Bulgaria
  • DCC "Alexandrovska", EOOD; Clinic of Neurology
    Sofia, 1431, Bulgaria
  • UMHAT "SofiaMed", OOD
    Sofia, 1750, Bulgaria
  • MC "Synexus - Sofia", EOOD
    Sofia, 1784, Bulgaria
  • MHAT Dr. St. Kirkovich, AD
    Stara Zagora, 6003, Bulgaria
  • 'New Medical Center' , EOOD
    Vratsa, 3000, Bulgaria
  • Centro de Reumatologia y Ortopedia
    Barranquilla, 80020, Colombia
  • Centro de Investigacion en Reumatologia y Especialdades Medicas SAS. CIREEM
    Bogota, 110221, Colombia
  • Riesgo de Fractura S.A.
    Bogota, 110221, Colombia
  • Fundación Instituto de Reumatología Fernando Chalem
    Bogota, 111211, Colombia
  • Clinica de Artritis Temprana S.A.
    Cali, 00000, Colombia
  • Hospital Pablo Tobon Uribe
    Medellin, 050034, Colombia
  • Chungnam National University Hospital; Department of Internal Medicine (Rheumatology)
    Daejeon, 35015, Korea, Republic of
  • Chonnam National University Hospital
    Gwangju, 61469, Korea, Republic of
  • Seoul National University Bundang Hospital
    Gyeonggi-do, 13620, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Konkuk University Medical Center
    Seoul, 05030, Korea, Republic of
  • Asan Medical Center - Oncology
    Seoul, 05505, Korea, Republic of
  • Ajou University Hospital
    Suwon City, 443-721, Korea, Republic of
  • Consultorio Medico en Fundacion el Hospitalito de morelos A.C.
    Cuernavaca, Morelos 62170, Mexico
  • Centro de Investigación de Tratamientos Innovadores de Sinaloa (CITI)
    Culiacán Rosales, Sinaloa 80000, Mexico
  • Centro de Investigacion en Reumatologia
    Merida, Yucatan 97070, Mexico
  • Consultorio Particular del Dr. Miguel Cortes Hernandez
    Cuernavaca, 62290, Mexico
  • Centro de Investigacion en Enfermedades Reumaticas y Osteoporosis
    Mexicali, 21100, Mexico
  • Centro de Investigacion Clínica GRAMEL S.C
    Mexico, 03720, Mexico
  • Policilinica Medica de Queretaro; Rheumatology
    Queretaro, 76000, Mexico
  • Clinical Research Institute
    Tlalnepantla, 54055, Mexico
  • Unidad de Enfermedades Reumaticas y Cronicodegenerativas
    Torreon, 27000, Mexico
  • NZOZ OSTEO-MEDIC S.C. Artur Racewicz, Jerzy Supronik
    Bialystok, 15-351, Poland
  • Szpital Uniwersytecki; nr 2 im. Dr J. Biziela
    Bydgoszcz, 85-168, Poland
  • Medica Pro Familia Spolka Akcyjna Oddzial w Katowicach
    Katowice, 40-081, Poland
  • Centrum Medyczne Plejady
    Krakow, 30-349, Poland
  • CCBR - Lodz - PL
    Lodz, 90-368, Poland
  • ETYKA Osrodek Badan Kliniczynch
    Olsztyn, 10-117, Poland
  • Ai Centrum Medyczne Sp. Z O.O Sp.K.
    Poznan, 61-113, Poland
  • KO-MED Centra Kliniczne Staszow
    Staszow, 28-200, Poland
  • Medycyna Kliniczna
    Warszawa, 00-660, Poland
  • Centrum Medyczne AMED
    Warszawa, 03-291, Poland
  • Wojewódzki Szpital Specjalistyczny we Wrocławiu
    Wrocław, 51-124, Poland
  • KO-MED Centra Kliniczne Zamosc
    Zamosc, 22400, Poland
  • TSBIH "Krasnoyarsk Interdistrict Clinical Hospital of Emergency Medical Care n.a. N.S. Karpovich
    Krasnoyarsk, Krasnojarsk 660062, Russian Federation
  • Federal State Budgetary Scientific Institution Research Institute of Rheumatology V.A. Nasonova
    Moscow, Moskovskaja Oblast 115522, Russian Federation
  • SBIH of Moscow "City Clinical Hospital # 1 n. a. N. I. Pirogov"
    Moscow, Moskovskaja Oblast 119049, Russian Federation

Showing the first 100 of 150 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Jul 2018, 21 months.

Results were first posted in Sep 2019, 1 year 2 months after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 21 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2016
First posted
Jul 14, 2016
StartActual
Sep 9, 2016
Primary completionActual
Jul 2, 2018
CompletionActual
Jul 2, 2018
Results first posted
Sep 10, 2019
Last update
Jun 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02833350
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Jul 14, 2016
Start date
Sep 9, 2016
Primary completion
Jul 2, 2018
Completion
Jul 2, 2018
Results posted
Sep 10, 2019
Last update
Jun 12, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fenebrutinib

Start the discussion